Comparative Pharmacology
Head-to-head clinical analysis: BUTAZOLIDIN versus DICLOFENAC SODIUM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BUTAZOLIDIN versus DICLOFENAC SODIUM.
BUTAZOLIDIN vs DICLOFENAC SODIUM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2), thereby reducing prostaglandin synthesis. Also has uricosuric effect at higher doses.
Non-selective COX-1 and COX-2 inhibitor, reducing prostaglandin synthesis via inhibition of cyclooxygenase, leading to anti-inflammatory, analgesic, and antipyretic effects.
Butazolidin (phenylbutazone) is typically administered orally at 100-200 mg 3 times daily with meals, not to exceed 600 mg/day. Initial loading dose of 400 mg may be given on day 1, followed by 300-400 mg/day in divided doses. Duration should be limited to 7-10 days.
Oral: 50 mg two to three times daily; maximum 150 mg/day. Topical: 1% gel applied four times daily. Rectal: 100 mg suppository once daily.
None Documented
None Documented
Terminal half-life: 50-100 hours (prolonged in elderly or hepatic/renal impairment; accumulation risk evident within 5-7 days).
Terminal elimination half-life approximately 2 hours (range 1.3–3.1 h). Short half-life requires frequent dosing; no accumulation with normal dosing intervals.
Primarily renal: ~60% as unchanged drug and glucuronide conjugates; biliary/fecal: ~40% (enterohepatic circulation).
Approximately 65% renal as glucuronide conjugates and inactive metabolites, ~20% biliary/fecal. Less than 1% unchanged in urine.
Category C
Category D/X
NSAID
NSAID